392 related articles for article (PubMed ID: 15295613)
1. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
2. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Fogari R; Mugellini A; Derosa G;
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
5. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
6. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
[TBL] [Abstract][Full Text] [Related]
7. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
8. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
9. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Kincaid-Smith P; Fairley KF; Packham D
Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
[TBL] [Abstract][Full Text] [Related]
10. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Mori-Takeyama U; Minatoguchi S; Murata I; Fujiwara H; Ozaki Y; Ohno M; Oda H; Ohashi H
Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
[TBL] [Abstract][Full Text] [Related]
11. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
Matsuda H; Hayashi K; Saruta T
J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
[TBL] [Abstract][Full Text] [Related]
13. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
[TBL] [Abstract][Full Text] [Related]
14. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
15. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
[TBL] [Abstract][Full Text] [Related]
16. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
[TBL] [Abstract][Full Text] [Related]
17. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
18. Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Fogari R; Corradi L; Zoppi A; Lazzari P; Mugellini A; Preti P; Rinaldi A
Am J Hypertens; 2007 Oct; 20(10):1092-6. PubMed ID: 17903693
[TBL] [Abstract][Full Text] [Related]
19. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]